Syn th esis of th e Azir id in om itosen e Sk eleton by In tr a m olecu la r
Mich a el Ad d ition : r-Lith ioa zir id in es a n d Non a r om a tic Su bstr a tes
Edwin Vedejs,*,‡ J eremy D. Little,‡ and Lisa M. Seaney†
Chemistry Department, University of Wisconsin, Madison, Wisconsin 53706, and
Department of Chemistry, University of Michigan, Ann Arbor, Michigan 48109
edved@umich.edu
Received J uly 14, 2003
The bicyclic pyrrole ketone 16 has been prepared by using an oxaza-Claisen rearrangement, followed
by nitrogen deprotection. Coupling with the stannylaziridine mesylate 15a or nosylate 15b affords
17. Conversion to 40 provides a substrate for generation of an R-lithioaziridine 41 by tin lithium
exchange. An intramolecular Michael addition pathway for 41 has been demonstrated by the
isolation of 46 in 20% yield under conditions where the intermediate enolate 43 is trapped by
selenenylation, but competing proton transfer gives 42. The synthetic potential of the process is
limited by stability problems at the stage of the enolate 43 or the protonated product 44.
There has been considerable interest in the “FR”
compounds 1 and 2 due to their potent antitumor
activity.1,2 However, clinical trials of a related structure
(FK973) encountered vascular leak syndrome (VLS).3
Subsequent efforts to develop a drug candidate lacking
this side effect have resulted in the discovery of FK317,
a semisynthetic substance that retains high potency
without inducing VLS.4 This observation has revived
interest in the “FR” series, and has refocused attention
on the mode of action of these unusual molecules. A
multistage activation mechanism has been proposed for
the “FR” compounds, featuring reductive N-O bond
cleavage followed by cyclization and aromatization to the
labile tetracyclic intermediates 4 and 5.5 These structures
bear a close resemblance to the leucoaziridinomitosenes
that play an important role as intermediates in the
reductive activation of mitomycins, and in DNA cross-
linking events that are responsible for their antitumor
activity.6 Strong evidence has been advanced to support
a similar mode of action by 4 and 5,7 and it is likely that
analogous structures such as 6 and 7 may be involved in
the activation sequence from FK317 (3).4 So far, none of
the proposed structures 4-7 have been observed directly
or generated by total synthesis, although progress toward
the tetracyclic skeleton has been reported.2
We have initiated a program designed to prepare 6 and
7 for the eventual study of their role in the activation
cascade from FK317. Two closely related approaches have
been investigated in parallel studies, based on the
proposition that intramolecular nucleophilic addition
starting from R-tributylstannylaziridines 8 or 10 may
allow synthetic access to the tetracyclic structures 9 or
11. The key cyclization step in the aromatic series (8 to
9) has been achieved, as described in a preliminary report
from our laboratory, and detailed in the accompanying
paper.8 Here, we report our earlier efforts to develop an
approach based on nonaromatic precursors related to 10.
The synthesis exploits prior methodology developed in
our group for the generation of R-lithioaziridines.9 While
our work was under way,10 Ziegler et al. described a
strategically similar approach to tetracyclic aziridino-
mitosanes such as 14, based on the cyclization of aziri-
dinyl radicals generated from the intermediates 12 and
13.11 The sequence is similar for its timing of bond-
forming events leading to the key tetracycle 14. However,
product 14 does not have the indole double bond that is
essential for activation of potential leaving groups (CH2-
OC(O)NH2; aziridine C-N) and for DNA cross-linking.
Because of this difference, 14 is a relatively stable
molecule compared to 11 and related structures where
the allylic aziridine C-N bond is activated for heterolysis
by the pyrrole subunit.
‡ University of Michigan.
† University of Wisconsin.
(1) Kiyoto, S.; Shibata, T.; Yamashita, M.; Komori, T.; Okuhara, M.;
Terano, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. J . Antibiot. 1987, 40,
594. Kiyoto, S.; Shibata, T.; Yamashita, M.; Komori, T.; Okuhara, M.;
Terano, H.; Kohsaka, M.; Aoki, H.; Imanaka, H. J . Antibiot. 1989, 42,
145.
(2) Review: Danishefsky, S. J .; Schkeryantz, J . M. Synlett 1995,
475. A summary and listing of key references is provided in the
following article.
(3) Pazdur, R.; Ho, D. H.; Daugherty, K.; Bradner, W. T.; Krakoff,
I. H.; Raber, M. N. Invest. New Drugs 1991, 9, 337.
(4) Naoe, Y.; Inami, M.; Matsumoto, S.; Nishigaki, F.; Tsujimoto,
S.; Kawamura, I.; Miyayasu, K.; Manda, T.; Shimomura, K. Cancer
Chemother. Pharmacol. 1998, 42, 31.
(5) Fukuyama, T.; Goto, S. Tetrahedron Lett. 1989, 30, 6491.
(6) DNA alkylation reviews: (a) Rajski, S. R.; Williams, R. M. Chem.
Rev. 1998, 98, 2723. (b) Tomasz, M.; Palom, Y. Pharmacol. Ther. 1997,
76, 73. (c) Tomasz, M. Chem. Biol. 1995, 2, 575. For a review of
synthetic approaches see ref 2.
(7) Huang, H.; Pratum, T. K.; Hopkins, P. B. J . Am. Chem. Soc.
1994, 116, 2703. Paz, M. M.; Hopkins, P. B. J . Am. Chem. Soc. 1997,
119, 5999. J udd, T. C.; Williams, R. M. Org. Lett. 2002, 4, 3711.
(8) Companion paper : Vedejs, E.; Little, J . D. J . Org. Chem. 2003,
68, 1794.
(9) Vedejs, E.; Moss, W. O. J . Am. Chem. Soc. 1993, 115, 1607.
(10) Seaney, L. M. Ph.D. Dissertation, University of Wisconsin, 1995.
(11) (a) Ziegler, F. E.; Belema, M. J . Org. Chem. 1994, 59, 7962. (b)
Ziegler, F. E.; Belema, M. J . Org. Chem. 1997, 62, 1083. (c) Ziegler, F.
E.; Berlin, M. Y. Tetrahedron Lett. 1998, 39, 2455.
10.1021/jo030224a CCC: $27.50 © 2004 American Chemical Society
Published on Web 01/15/2004
1788
J . Org. Chem. 2004, 69, 1788-1793